Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Front Vet Sci ; 9: 1031976, 2022.
Article in English | MEDLINE | ID: mdl-36337207

ABSTRACT

The science and technology of laboratory animals has come a long way worldwide, but for reasons related to the development of the countries, this journey started later in some Latin American countries, as is the case of Argentina. Without a specific legal framework to conduct animal experimentation, local strengths to promote animal welfare are based on professionals specifically trained in the care of laboratory animals as well as an extended network of ethics committees that ensures compliance with the ethical principles applied to animal experimentation. Nevertheless, there are no updated reports showing welfare indicators in rodent facilities. Therefore, we conducted a survey on mice breeding facilities enrolled in a national record elaborated by the National Ministry of Science. Questions related to four of the Five Domains Model of Mellor, concerning (1) nutrition, (2) physical environment, (3) health, and (4) behavioral interactions with the environment, other animals, and humans, were included as well as information concerning general aspects of the establishments. Data obtained from 25 mice breeder facilities localized all over the country were summarized, providing for the first time a clear picture of the national situation about the welfare of laboratory mice in these establishments. This data will be essential to design future policy as well as for deciding priorities aiming to improve the welfare of mice bred in Argentinian facilities.

2.
Spat Spatiotemporal Epidemiol ; 36: 100393, 2021 02.
Article in English | MEDLINE | ID: mdl-33509433

ABSTRACT

The Lithium Triangle in the Andean plateau involves high altitude (>3,000 m asl) hydrological systems having high lithium graded waters. This research was carried-out in rural areas of north westernmost Argentinean Andes and was aimed: 1) to determine concentrations of lithium in drinking waters; 2) to calculate suicide mortality rates based on available official data (2003-2013); 3) to analyze bivariate differences between lithium concentrations in drinking water, mean rates of suicide mortality, altitude of sampling sites, and water sources; 4) to analyze bivariate correlations between lithium concentrations in drinking water, mean rates of suicide mortality, and altitude; 5) to test predictive models for mean rates of suicide mortality, when considering the predictors lithium concentrations in drinking water, altitude, and water sources. Lithium determinations in drinking waters were performed by Microwave Plasma-Atomic Emission Spectrometer. Nonparametric tests were applied to analyze differences and correlations. Generalized linear models (GLM) were used to fitting models for mean rates of suicide. Drinking waters contained up to 2.98 mg L-1 of lithium. Mean rates of suicide mortality (per 100,000 inhabitants) were high, ranging from 19.12 (± 19.83) to 30.22 (± 16.70). Lithium but not altitude was positively correlated with suicide mortality when analyzing bivariate correlations (Li: rho = 0.76, p-value < 0.001). However, when GLM were calculated, a significant interaction effect was found between lithium and altitude (p-value < 0.001). This interaction effect would act in some way restraining the suicide mortality rates.


Subject(s)
Drinking Water , Suicide , Altitude , Humans , Linear Models , Lithium/analysis
3.
Front Cell Neurosci ; 13: 384, 2019.
Article in English | MEDLINE | ID: mdl-31555094

ABSTRACT

Neurotrophic factors are relevant regulators of the neurogenic process at different levels. In particular, the brain-derived neurotrophic factor, BDNF, is highly expressed in the hippocampus (HC) of rodents and participates in the control of neuronal proliferation, and survival in the dentate gyrus (DG). Likewise, serotonin is also involved in the regulation of neurogenesis, though its role is apparently more complex. Indeed, both enhancement of serotonin neurotransmission as well as serotonin depletion, paradoxically increase neuronal survival in the HC of mice. In this study, we analyzed the protein expression of the BDNF isoforms, i.e., pro- and mature-BDNF, and their respective receptors p75 and TrkB, in the HC of mice chronically treated with para-chloro-phenyl-alanine (PCPA), an inhibitor of serotonin synthesis. The same analysis was conducted in hyposerotonergic mice with concomitant administration of the 5-HT1 A receptor agonist, 8-Hydroxy-2-(di-n- propylamino) tetralin (8-OH-DPAT). Increased expression of p75 receptor with decreased expression of pro-BDNF was observed after chronic PCPA. Seven-day treatment with 8-OH-DPAT reestablished the expression of pro-BDNF modified by PCPA, and induced an increase in the expression of p75 receptor. It has been demonstrated that PCPA-treated mice have higher number of immature neurons in the HC. Given that immature neurons participate in the pattern separation process, the object pattern separation test was conducted. A better performance of hyposerotonergic mice was not confirmed in this assay. Altogether, our results show that molecules in the BDNF signaling pathway are differentially expressed under diverse configurations of the serotonergic system, allowing for fine-tuning of the neurogenic process.

4.
J Neurochem ; 138(2): 204-21, 2016 07.
Article in English | MEDLINE | ID: mdl-27167299

ABSTRACT

The brain-derived neurotrophic factor, BDNF, was discovered more than 30 years ago and, like other members of the neurotrophin family, this neuropeptide is synthetized as a proneurotrophin, the pro-BDNF, which is further cleaved to yield mature BDNF. The myriad of actions of these two BDNF isoforms in the central nervous system is constantly increasing and requires the development of sophisticated tools and animal models to refine our understanding. This review is focused on BDNF isoforms, their participation in the process of neurogenesis taking place in the hippocampus of adult mammals, and the modulation of their expression by serotonergic agents. Interestingly, around this triumvirate of BDNF, serotonin, and neurogenesis, a series of recent research has emerged with apparently counterintuitive results. This calls for an exhaustive analysis of the data published so far and encourages thorough work in the quest for new hypotheses in the field. BDNF is synthetized as a pre-proneurotrophin. After removal of the pre-region, proBDNF can be cleaved by intracellular or extracellular proteases. Mature BDNF can bind TrkB receptors, promoting their homodimerization and intracellular phosphorylation. Phosphorylated-TrkB can activate three different signaling pathways. Whereas G-protein-coupled receptors can transactivate TrkB receptors, truncated forms can inhibit mBDNF signaling. Pro-BDNF binds p75(NTR) by its mature domain, whereas the pro-region binds co-receptors.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Neurogenesis , Protein Isoforms/metabolism , Protein Precursors/metabolism , Serotonin Agents/pharmacology , Serotonin/metabolism , Animals , Humans , Neurogenesis/drug effects , Neurogenesis/physiology
5.
Eur Neuropsychopharmacol ; 26(2): 265-279, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26727039

ABSTRACT

Depressive disorders are among the most prevalent neuropsychiatric dysfunctions worldwide, with high rates of resistance to antidepressant treatment. Genetic factors clearly contribute to the manifestation of depression as well as to the response to antidepressants. Transgenic mouse models appear as seminal tools to disentangle this complex disorder. Here, we analyzed new key aspects of the phenotype of knock-out mice for the gene encoding the serotonin 2B receptor (Htr(2B)(-/-)), including basal phenotype, ability to develop a depressive-like phenotype upon chronic isolation, and effect of chronic exposure to fluoxetine on chronically stressed Htr(2B)(-/-) mice. We find, here, that Htr(2B)(-/-) mice display an antidepressant-like phenotype, which includes reduced latency to feed in the novelty suppressed feeding test, basal increase in hippocampal BDNF levels, no change in TrkB and p75 protein levels, and an increased preference for sucrose consumption compared to wild type (Htr(2B)(+/+)) mice. Nevertheless, we show that these mice can develop depressive-like behaviors when socially isolated during four weeks. Selective serotonin reuptake inhibitors (SSRI) have been previously shown to be ineffective in non-stressed Htr(2B)(-/-) mice. We evaluated, here, the effects of the SSRI fluoxetine in chronically stressed Htr(2B)(-/-) mice and similarly no behavioral or plastic effect was induced by this antidepressant. All together, these results highlight the suitability to study resistance to SSRI antidepressants of this mouse model displaying panoply of conditions among which behavioral, neurotrophic and plastic causative factors can be analyzed.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , Depressive Disorder/genetics , Receptor, Serotonin, 5-HT2B/deficiency , Selective Serotonin Reuptake Inhibitors/therapeutic use , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cell Proliferation/drug effects , Cell Proliferation/genetics , Depressive Disorder/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Feeding Behavior/drug effects , Hippocampus/drug effects , Hippocampus/physiopathology , Locomotion/drug effects , Locomotion/genetics , Male , Maze Learning/drug effects , Mice , Mice, Transgenic , Protein Binding/drug effects , Protein Binding/genetics , Reaction Time/drug effects , Receptor, Serotonin, 5-HT2B/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Serotonin Plasma Membrane Transport Proteins/metabolism , Swimming/psychology
6.
Neuropharmacology ; 61(3): 495-502, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21277875

ABSTRACT

The serotonin (5-HT) syndrome occurs in humans after antidepressant overdose or combination of drugs inducing a massive increase in extracellular 5-HT. Several 5-HT receptors are known to participate in this syndrome in humans and animal models. The 5-HT(2B) receptor has been proposed as a positive modulator of serotonergic activity, but whether it is involved in 5-HT syndrome has not yet been studied. We analyzed here, a putative role of 5-HT(2B) receptors in this disorder by forced swimming test (FST) and behavioral assessment in the open field. In FST, genetic (5-HT(2B)(-/-) mice) or pharmacological (antagonist RS127445 at 0.5 mg/kg) ablation of 5-HT(2B) receptors facilitated selective 5-HT reuptake inhibitors (SSRI)-induced increase of immobility time as well as expression of other symptoms related to 5-HT syndrome like hind limb abduction and Straub tail. Increase in immobility was also developed in FST by both wild type (WT) and 5-HT(2B)(-/-) mice after the administration of 5-HT(1A), 5-HT(2A) or 5-HT(2C) receptor agonists, 8-OH-DPAT (5 mg/kg), DOI (1 mg/kg), or WAY161503 (5 mg/kg), respectively. In contrast, the 5-HT(2B) receptor agonist BW723C86 (3 mg/kg) or 5-HT(1B) receptor agonist CGS12066A (2 mg/kg) decreased immobility time in both genotypes. The 5-HT syndrome induced by fluoxetine at high doses was blocked in WT and 5-HT(2B)(-/-) mice by administration of 5-HT(1A) and 5-HT(2C) receptor antagonists (WAY100635 0.5 mg/kg and SB242084 0.5 mg/kg) but not by the 5-HT(2A) receptor antagonist MDL100907 (1 mg/kg). By behavioral assessment, we confirmed that 5-HT(2B)(-/-) mice were more prone to develop 5-HT syndrome symptoms after administration of high dose of SSRIs or the 5-HT precursor 5-Hydroxytryptophan, 5-HTP, even if increases in 5-HT plasma levels were similar in both genotypes. This evidence suggests that the presence of 5-HT(2B) receptors hinders acute 5-HT toxicity once high levels of 5-HT are attained. Therefore, differential agonism/antagonism of 5-HT receptors should be considered in the search of therapeutic targets for treating this serious disorder.


Subject(s)
Receptor, Serotonin, 5-HT2B/physiology , Serotonin Syndrome/metabolism , 5-Hydroxytryptophan/administration & dosage , 5-Hydroxytryptophan/toxicity , Animals , Behavior, Animal/drug effects , Depression/chemically induced , Depression/etiology , Depression/metabolism , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Male , Mice , Mice, 129 Strain , Mice, Transgenic , Motor Activity/drug effects , Pyrimidines/toxicity , Random Allocation , Receptor, Serotonin, 5-HT1B/chemistry , Receptor, Serotonin, 5-HT2B/chemistry , Receptor, Serotonin, 5-HT2B/genetics , Serotonin/blood , Serotonin 5-HT1 Receptor Agonists/therapeutic use , Serotonin 5-HT2 Receptor Agonists/therapeutic use , Serotonin 5-HT2 Receptor Antagonists/toxicity , Serotonin Receptor Agonists/toxicity , Serotonin Syndrome/blood , Serotonin Syndrome/drug therapy , Serotonin Syndrome/physiopathology , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL